UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36571 T2 Biosystems, Inc. (Exact name of registrant as specified in its charter) Delaware 20-4827488 (State or other jurisd ...

T2 Biosystems, Inc. (NASDAQ:TTOO) Q3 2019 Earnings Conference Call November 12, 2019 8:30 AM ET Company Participants Zack Kubow - W2O Group John McDonough - Chairman and CEO John Sprague - CFO Tom Lowery - Chief Scientific Officer Conference Call Participants Puneet Souda - SVB Leerink Partners Mark Massaro - Canaccord Genuity Paul Knight - Janney Montgomery Scott Steve Brozak - WBB Securities Ben Haynor - Alliance Global Partners Operator Greetings. Welcome to the T2 Biosystems' 2019 Third Quarter Financia ...

Click to edit Master subtitle style Breakthrough Sepsis Pathogen Detection Click to edit Master title style Corporate Presentation October 2019 (NASDAQ: TTOO) CORPORATE PRESENTATION Forward-Looking Statements 2 This presentation contains forward-looking statements. Such statements reflect the current views of senior management of T2 Biosystems, Inc. ("we", "us", "our", "T2", "T2 Biosystems" or the "Company") and include those about T2's goals, strategies, plans, objectives, prospects, milestones, future ope ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36571 T2 Biosystems, Inc. Securities registered pursuant to Section 12(b) of the Act: | | Trading | | | --- | --- | --- | | Titl ...

T2 Biosystems, Inc. (NASDAQ:TTOO) Q2 2019 Earnings Conference Call July 30, 2019 4:30 PM ET Company Participants Matt Clawson - Investor Relations John McDonough - President & Chief Executive Officer John Sprague - Chief Financial Officer Tom Lowery - Chief Scientific Officer Sandy Estrada - Vice President Medical Affairs Conference Call Participants Patrick Donnelly - Goldman Sachs Puneet Souda - SVB Leerink Mark Massaro - Canaccord Genuity Steve Brozak - WBB Securities Jordan Abrams - Cantor Fitzgerald Yi ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-36571 T2 Biosystems, Inc. (Exact name of registrant as specified in its charter) Delaware 20-4827488 (State or other jurisdicti ...

T2 Biosystems, Inc. (NASDAQ:TTOO) Q1 2019 Earnings Conference Call May 2, 2019 4:30 PM ET Company Participants Zack Kubow - W2O Group John McDonough - CEO, President & Director John Sprague - CFO & SVP Thomas Lowery - Chief Scientific Officer Conference Call Participants Jordan Abrams - Cantor Fitzgerald & Co. Mark Massaro - Canaccord Genuity Limited Stephen Brozak - WBB Securities Casey Woodring - Janney Yi Chen - H.C. Wainwright & Co. Soumit Roy - JonesTrading Institutional Services Operator Welcome to th ...

Breakthrough Sepsis Pathogen Detection Click to edit Master title Click to edit Master subtitle style style Corporate Presentation April 2019 (NASDAQ: TTOO) CORPORATE PRESENTATION Forward-Looking Statements 2 This presentation contains forward-looking statements. Such statements reflect the current views of senior management of T2 Biosystems, Inc. ("we", "us", "our", "T2", "T2 Biosystems" or the "Company") and include those about T2's goals, strategies, plans, objectives, prospects, milestones, future opera ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the year ended December 31, 2018 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-36571 T2 Biosystems, Inc. (Exact name of registrant as specified in its charter) | Delaware | 20-4827488 | | --- | --- | | (State or other jur ...

T2 Biosystems, Inc. (NASDAQ:TTOO) Q4 2018 Results Earnings Conference Call March 8, 2019 4:30 PM ET Company Participants Zack Kubow - Investor Contact, W2O Group John McDonough - Chief Executive Officer John Sprague - Chief Financial Officer Conference Call Participants Stephen Brozak - WBB Securities Max Masucci - Canaccord Genuity Patrick Donnelly - Goldman Sachs Paul Knight - Janney Capital Markets Jordan Abrams - Cantor Fitzgerald Soumit Roy - JonesTrading Edward Marks - HC Wainwright Puneet Souda - Lee ...